Recent
price
P/E
ratio
div
yld
- -
ROIC.AI
•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Ocugen Eyes 2027 Trial Results and FDA Filing for Lead Gene Therapy
Ocugen and Celairis Therapeutics Enter into Exclusive License Agreement for OCU400 in Australia, New Zealand, and ASEAN
Ocugen's Q3 Earnings Match Estimates, Revenues Beat, Stock Rises
Ocugen, Inc. (OCGN) Q3 2026 Earnings Call Transcript
Ocugen Q3 Earnings Call Highlights
Ocugen (OCGN) Reports Q3 Loss, Tops Revenue Estimates
Ocugen Provides Business Update with Third Quarter 2026 Financial Results
Ocugen to Participate in Upcoming November Investor and Industry Conferences
Ocugen to Provide Business Update and Third Quarter 2026 Financial Results on November 4
Ocugen and Roots Pharmaceutical Complete License Agreement for OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa
Did Ocugen, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Hemostemix Announces Full LARTA Approval, Manufacturing Progress and Financing Update
Ocugen Appoints Industry Executive Jolanda Crombach General Manager of European Affiliate
Ocugen to Participate in Upcoming Scientific Conferences
Ocugen to Participate in Upcoming October Investor and Industry Conferences
Ocugen Receives Provisional Approval and Priority Designation Under the Longevity and Regenerative Therapies Act in The Bahamas to Provide OCU400 to Patients for Treatment of Retinitis Pigmentosa
Ocugen Targets Three Gene Therapy BLA Filings as Retinal Pipeline Advances
Ocugen: Q3 Data Catalyst In Stargardt Disease Feels Critical
OCGN Advances Gene Therapy OCU410 In Phase III for Geographic Atrophy
Ocugen Announces First Patient Dosed in Phase 3 Registrational Trial of OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration